SOPHiA GENETICS SA: insider trades · United States · SEC (Form 4)

About SOPHiA GENETICS SA

SOPHiA GENETICS SA is a digital health company listed on the U.S. Nasdaq exchange (United States) under the ticker SOPH. Founded in 2011 by biologists, the company was built around a simple but ambitious goal: make complex medical data analysis more accessible and clinically useful. Its headquarters are in Rolle, Switzerland, with an established U.S. presence in Boston and additional international operations. For French-speaking investors, the business sits at the intersection of healthcare software, genomics, and AI-enabled precision medicine. The company’s core asset is the cloud-native SOPHiA DDM™ platform, which analyzes genomic and multimodal data and converts it into actionable insights for hospitals, laboratories, and biopharma partners. SOPHiA GENETICS says more than 990 healthcare institutions use its platform across more than 75 countries, giving it a broad global footprint and an important network effect. Its main business lines include clinical genomics, oncology workflows, solid tumor testing, liquid biopsy applications, and collaborations with pharmaceutical companies for evidence generation, co-development, and companion-diagnostic-related work. Competitively, SOPHiA GENETICS operates in a highly specialized market where software quality, clinical workflow integration, regulatory compliance, and dataset depth matter more than generic IT capabilities. The company differentiates itself through a cloud-native, consumption-based SaaS model rather than a one-off software sale. That positioning allows it to serve large academic hospitals, reference laboratories, and biopharma clients, while building recurring usage and long-term customer relationships. Recent developments point to improving commercial momentum. In the first quarter of 2026, the company reported 22% year-over-year revenue growth, a record 108,000 genomic analyses performed on SOPHiA DDM™, and growth in its core genomics customer base to 537 customers. Management also highlighted stronger U.S. traction, including new wins with major health systems, alongside continued expansion in Europe. In May 2026, SOPHiA GENETICS announced a partnership with Synnovis in the U.K. to bring blood-based cancer testing to patients, and earlier in the year it disclosed a strategic collaboration with MD Anderson to accelerate AI-driven precision oncology. From an investor perspective, the key attraction is the company’s combination of international growth, deeper penetration in the U.S. market, and potential operating leverage as platform usage scales. SOPHiA GENETICS is still in a growth-and-investment phase, but it is clearly focused on expanding its installed base, broadening its application suite, and moving gradually toward profitability.